Harbeck, Nadia

Pembrolizumab for Early Triple-Negative Breast Cancer

Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 3,270

Breast cancer

Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 3,024

Palbociclib and letrozole in advanced breast cancer

Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 3,007

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,827

Palbociclib in hormone-receptor-positive advanced breast cancer

Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,590

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 1,369

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,276

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., et al. (2022) · New England Journal of Medicine

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 1,274

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., et al. (2020) · The Lancet

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 1,083

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,025

Overall survival with ribociclib plus endocrine therapy in breast cancer

Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,001

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 540

Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E. (2012) · Annals of Oncology

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 485

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., et al. (2019) · Breast Cancer Research and Treatment

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 443

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · The Breast

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 338

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

Lu, Y.-S., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Cardoso, F., Harbeck, N., Hurvitz, S., Chow, L., Sohn, J., et al. (2022) · Clinical Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 287

Management of venous port systems in oncology: a review of current evidence

Vescia, S., Baumgärtner, A. K., Jacobs, V. R., Kiechle-Bahat, M., Rody, A., Loibl, S., & Harbeck, N. (2008) · Annals of Oncology

Central Venous Catheters and HemodialysisNeutropenia and Cancer Infections

Cited by 264

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Cristofanilli, M., Rugo, H. S., Im, S.-A., Slamon, D. J., Harbeck, N., Bondarenko, I., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., et al. (2022) · Clinical Cancer Research

Advanced Breast Cancer TherapiesPARP inhibition in cancer therapy

Cited by 207

Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

Slamon, D. J., Diéras, V., Rugo, H. S., Harbeck, N., Im, S.-A., Gelmon, K. A., Lipatov, O. N., Walshe, J. M., Martin, M., Chavez-MacGregor, M., et al. (2024) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesPARP inhibition in cancer therapy

Cited by 200

Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.

Finn, R. S., Rugo, H. S., Dieras, V. C., Harbeck, N., Im, S.-A., Gelmon, K. A., Walshe, J. M., Martin, M., Chavez Mac Gregor, M., Bananis, E., et al. (2022) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 169

The patient’s anastrozole compliance to therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer

Hadji, P., Blettner, M., Harbeck, N., Jackisch, C., Lück, H.-J., Windemuth-Kieselbach, C., Zaun, S., & Kreienberg, R. (2013) · Annals of Oncology

Medication Adherence and ComplianceCancer survivorship and care

Cited by 122

Clinically assessed posttraumatic stress in patients with breast cancer during the first year after diagnosis in the prospective, longitudinal, controlled COGNICARES study

Voigt, V., Neufeld, F., Kaste, J., Bühner, M., Sckopke, P., Wuerstlein, R., Hellerhoff, K., Sztrókay-Gaul, A., Braun, M., von Koch, F. E., et al. (2017) · Psycho-Oncology

Cancer survivorship and carePosttraumatic Stress Disorder Research

Cited by 67

Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

Cristofanilli, M., Rugo, H. S., Im, S.-A., Slamon, D. J., Harbeck, N., Bondarenko, I., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., et al. (2021) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesPARP inhibition in cancer therapy

Cited by 65

A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: Qualitative Study and Application Development

Schinköthe, T., Gabri, M. R., Mitterer, M., Gouveia, P., Heinemann, V., Harbeck, N., & Subklewe, M. (2020) · JMIR Public Health and Surveillance

Telemedicine and Telehealth ImplementationMobile Health and mHealth Applications

Cited by 64